Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BY 4.0PLOS One

Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study

  • Mohamed Ahmed El Maghawry1
  • Reham Abd Elkhalek2
  • Fatima Altaher Taha3
  • Amira A. A. Othman4
  • Aliaa Mohamed Abd El Khalik Ahmed5
  • Dina A. Abdelhady
  • Fatma M. Attia Elsayed
5 affiliations
  1. 1Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  2. 2Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  3. 3Internal Medicine Department, Faculty of Medicine, Suez University, Suez, Egypt
  4. 4Neurology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
  5. 5Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
Open at sourcePDFDOICite

Abstract

Background: Real-world evidence on therapeutic plasma exchange (TPE) from low- and middle-income countries remains limited. Egyptian data across multiple organ systems are scarce. This study aimed to evaluate the indications, safety, efficacy, and predictors of outcomes in patients undergoing TPE at a tertiary center in Egypt over 7 years. Methods and Findings: This retrospective cohort study included 221 consecutive patients who underwent TPE (2016–2022) at Zagazig University Hospitals, Egypt. Patients were stratified into renal, neurologic, hematologic, and metabolic groups. Primary outcomes were clinical response and all-cause mortality. Multivariate logistic regression, Cox proportional hazards models, and Kaplan–Meier survival analysis were performed. Among 221 patients (57.9% male; mean age 36.0 years), the most frequent indications were Guillain–Barré syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis crisis. ASFA category I indications constituted 77.8% of procedures, with response rates decreasing significantly across categories (p = 0.03). Overall response rate was 77.9% (complete remission in 93.0% of responders), with mortality 14.5%. Response rates exceeded 85% in autoimmune hemolytic anemia, hyperviscosity syndrome, and TTP. Neurologic indications achieved 81.6% response; renal indications showed lower response (73.2%) and highest mortality (21.3%). Adverse events occurred in 37.2% of patients, all mild-to-moderate with no session terminations. Independent mortality predictors included mechanical ventilation, creatinine >2.5 mg/dL, renal indication, hemoglobin <8 g/dL, while ASFA category I was protective (all aORs 2.67–5.22). In exploratory analyses, PLASMIC score ≥6 and time to TPE ≤ 2 days were associated with complete remission in TTP, while Hughes score ≥4 and time to TPE > 7 days were associated with poor functional outcome in GBS. These findings require external validation before clinical application. Diffuse alveolar hemorrhage (n = 9) demonstrated 100% mortality despite intervention, whereas SLE patients (n = 23) had 52.2% mortality, with 47.8% achieving complete remission or clinical improvement. A three-tier risk model stratified patients into high, intermediate, and low mortality risk groups. Independent predictors of clinical response included neurologic, hematologic, and metabolic indications compared to renal, ASFA category I, and ≥5 TPE sessions, while hemoglobin <8 g/dL and creatinine >2.5 mg/dL predicted poorer response. Conclusions: This single-center Egyptian TPE cohort demonstrates high efficacy and safety when aligned with ASFA guidelines. Neurologic and hematologic indications achieve optimal outcomes; renal indications and critical illness markers predict poorer prognosis. The PLASMIC score, treatment urgency in TTP and GBS, and the proposed three-tier model represent exploratory findings that, if prospectively validated, could become actionable prognostic tools. These findings suggest that evidence-based TPE expansion in resource-limited settings may be feasible, though multicenter validation is required.

Related

  1. Evaluating the efficacy and safety of therapeutic plasma exchange in snakebite-associated thrombotic microangiopathy compared to standard care alone: study protocol for a multicenter randomized controlled trial
    Eranga Wijewickrama, Bhawani Yasassri Alvitigala, Lallindra Gooneratne +8
    TrialsPeer-reviewedCC BY-NC-ND 4.0Genetics & genomicsCrossref
  2. Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications
    Ala’ Yousef, John M. Seubert, Christopher Power +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
  3. Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma
    Wenwen Cheng, Silvia Gaggero, Lama Hasan Bou Issa +25
    Biomarker ResearchPeer-reviewedCC BY-NC-NDFull textGeneral biologyHAL
  4. Engineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis
    C. Tian, Z. Ao, H. Cai +7
    bioRxivPreprintAll rights reservedFull textSystems & synthetic biologybioRxiv
  5. END nucleases are antiphage defence systems targeting multiple phages with modified genomes
    Wearn‐Xin Yee, Yan‐Jiun Lee, Kira S. Makarova +8
    Nature MicrobiologyPeer-reviewedLicence not stated12 citedEcologyMicrobiologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{maghawry2026therapeutic,
  title = {{Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study}},
  author = {Mohamed Ahmed El Maghawry and Reham Abd Elkhalek and Fatima Altaher Taha and Amira A. A. Othman and Aliaa Mohamed Abd El Khalik Ahmed and Dina A. Abdelhady and Fatma M. Attia Elsayed},
  journal = {PLOS One},
  year = {2026},
  month = sep,
  doi = {10.1371/journal.pone.0358069},
  url = {https://doi.org/10.1371/journal.pone.0358069},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study
AU  - Mohamed Ahmed El Maghawry
AU  - Reham Abd Elkhalek
AU  - Fatima Altaher Taha
AU  - Amira A. A. Othman
AU  - Aliaa Mohamed Abd El Khalik Ahmed
AU  - Dina A. Abdelhady
AU  - Fatma M. Attia Elsayed
PY  - 2026
DA  - 2026/09/11
JO  - PLOS One
DO  - 10.1371/journal.pone.0358069
UR  - https://doi.org/10.1371/journal.pone.0358069
AB  - Background: Real-world evidence on therapeutic plasma exchange (TPE) from low- and middle-income countries remains limited. Egyptian data across multiple organ systems are scarce. This study aimed to evaluate the indications, safety, efficacy, and predictors of outcomes in patients undergoing TPE at a tertiary center in Egypt over 7 years. Methods and Findings: This retrospective cohort study included 221 consecutive patients who underwent TPE (2016–2022) at Zagazig University Hospitals, Egypt. Patients were stratified into renal, neurologic, hematologic, and metabolic groups. Primary outcomes were clinical response and all-cause mortality. Multivariate logistic regression, Cox proportional hazards models, and Kaplan–Meier survival analysis were performed. Among 221 patients (57.9% male; mean age 36.0 years), the most frequent indications were Guillain–Barré syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis crisis. ASFA category I indications constituted 77.8% of procedures, with response rates decreasing significantly across categories (p = 0.03). Overall response rate was 77.9% (complete remission in 93.0% of responders), with mortality 14.5%. Response rates exceeded 85% in autoimmune hemolytic anemia, hyperviscosity syndrome, and TTP. Neurologic indications achieved 81.6% response; renal indications showed lower response (73.2%) and highest mortality (21.3%). Adverse events occurred in 37.2% of patients, all mild-to-moderate with no session terminations. Independent mortality predictors included mechanical ventilation, creatinine >2.5 mg/dL, renal indication, hemoglobin <8 g/dL, while ASFA category I was protective (all aORs 2.67–5.22). In exploratory analyses, PLASMIC score ≥6 and time to TPE ≤ 2 days were associated with complete remission in TTP, while Hughes score ≥4 and time to TPE > 7 days were associated with poor functional outcome in GBS. These findings require external validation before clinical application. Diffuse alveolar hemorrhage (n = 9) demonstrated 100% mortality despite intervention, whereas SLE patients (n = 23) had 52.2% mortality, with 47.8% achieving complete remission or clinical improvement. A three-tier risk model stratified patients into high, intermediate, and low mortality risk groups. Independent predictors of clinical response included neurologic, hematologic, and metabolic indications compared to renal, ASFA category I, and ≥5 TPE sessions, while hemoglobin <8 g/dL and creatinine >2.5 mg/dL predicted poorer response. Conclusions: This single-center Egyptian TPE cohort demonstrates high efficacy and safety when aligned with ASFA guidelines. Neurologic and hematologic indications achieve optimal outcomes; renal indications and critical illness markers predict poorer prognosis. The PLASMIC score, treatment urgency in TTP and GBS, and the proposed three-tier model represent exploratory findings that, if prospectively validated, could become actionable prognostic tools. These findings suggest that evidence-based TPE expansion in resource-limited settings may be feasible, though multicenter validation is required.
SN  - 1932-6203
ER  -